Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 3416

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Therapeutic
  • Drug Discovery
  • Disease
  • Pain
  • Immune
  • Arthritis
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3416

License Grant
The Licensor entered into a Collaboration Agreement with the Licensee in Hong Kong. The Licensee obtained an exclusive License to develop, manufacture and commercialize NOV-002 and NOV-205 in Hong Kong, Macau, China and Taiwan.
License Property
The two compounds are NOV-002, a cancer treatment, and NOV-205, which is used in the treatment of hepatitis. NOV-002 is Novelos' compound for the treatment of non-small cell lung cancer, and is currently undergoing phase III trials under Special Protocol Assessment (SPA), a status offered and recognized by the U.S. Food and Drug Administration.
Field of Use
The Field of Use apply to the medical industry.

IPSCIO Record ID: 5889

License Grant
The Licensee (Licensee Chairman of the Board of Directors is president of Licensor) revised its arrangement with the Licensor for an oxidized glutathione-based products.
Field of Use
The Licensee was established in 1996 to commercialize two promising oxidized glutathione-based compounds, NOV-002 and NOV-205, for the treatment of cancer and hepatitis.

IPSCIO Record ID: 26568

License Grant
Pursuant to a technology transfer Agreement between the Licensor of Russia, which the Company's directors is the majority shareholder for an oxidized glutathione-based products.
Field of Use
The field means to commercialize two promising oxidized glutathione-based compounds, NOV-002 and NOV-205, for the treatment of cancer and hepatitis.

IPSCIO Record ID: 367356

License Grant
Licensor grants to Licensee of Bermuda the exclusive, nontransferable and non-sublicenseable right to research, register, develop, make, have made, use, warehouse, promote, market, sell, have sold, import, distribute, and offer for sale the Licensed Products solely and exclusively in the Territory and the exclusive, non-transferable and non-sublicenseable  right to exploit the Licensor Technology in the Territory solely for the purpose of researching, registering, developing, making, having made, using, warehousing, promoting, marketing, selling, having sold, importing, distributing and offering for sale the Licensed Products in the Territory.
License Property
Licensor has intellectual property rights, technology and know-how related to oxidized glutathione-based compounds for the treatment of cancer and hepatitis.

The Lead Product shall mean xx-002, a combination of GSSG and cisplatin (10001 molar ratio), including the salts, esters, metabolites, tautomers, isomers, conjugates and complexes thereof.

Field of Use
The field of use is oncology.  The compound is used for the treatment of cancer and hepatitis.

NOV-002 is in a pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track. NOV-002 has also demonstrated positive results in Phase 2 trials for other cancer indications.  NOV-002 is also in Phase 2 development for early-stage breast cancer and chemotherapy-resistant ovarian cancer.

NOV-205 is in Phase 1b development for chronic hepatitis C non-responders.

IPSCIO Record ID: 276397

License Grant
Licensee obtains rights in mainland China, Hong Kong, Macau and Taiwan to develop and commercialize enoblituzumab.
License Property
Enoblituzumab is an investigational, Fc-optimized mAb that targets B7-H3. MacroGenics recently met with FDA to discuss its plans regarding a Phase 2/3 registration-directed study of enoblituzumab in combination with MGA012 in patients with squamous cell carcinoma of the head and neck (SCCHN).

A clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 319042

License Grant
Licensor and Hong Kong Licensee agreed to collaborate for the development and commercialization of uproleselan and GMI-1687 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China and to advance the preclinical and clinical development of GMI-1687.
License Property
GMI-1687 is a potential life-cycle extension to uproleselan that has been designed as an innovative antagonist of E-selectin that could be suitable for subcutaneous administration.

Uproleselan is a glycomimetic drug candidate and a specific E-selectin inhibitor that is being developed to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, or AML, a life-threatening hematologic cancer, and potentially other hematologic cancers.

E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering the circulation where they can be more readily killed by chemotherapy.  Glycomimetics are molecules that mimic the structure of carbohydrates involved in biological processes.

Field of Use
The field of use is for the treatment in combination with chemotherapy to treat patients with acute myeloid leukemia (AML) and potentially other hematologic cancers.

IPSCIO Record ID: 313340

License Grant
The Licensor granted Chinese Licensee an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Licensor, to develop, manufacture and commercialize Vicineumâ„¢ (the Licensed Product) for the treatment of non-muscle invasive bladder cancer (NMIBC) and other types of cancer (the Field) in China, Hong Kong, Macau and Taiwan (the Territory). The Licensor also granted Licensee a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Licensor to develop, manufacture and commercialize the Licensed Product in the Territory. The Licensor retains development, manufacturing and commercialization rights with respect to Vicineum in the rest of the world.
License Property
Licensed Product means VicineumTM, also known as VB4-845, a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A. The Licensor has an ongoing single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with high-risk, bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) (the VISTA Trial).

Licensor is a late-stage clinical company developing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer.

Field of Use
“Field” means the prevention and treatment of cancers, including; but not limited to, high-risk non-muscle invasive bladder cancer (“NMIBC”), and various sub-types of NMIBC.

IPSCIO Record ID: 217567

License Grant
Licensor granted Chinese Licensee an exclusive license to use Licensor’s patents, know-how, data and other intellectual property relating to Licensor’s AE37 peptide to develop and sell products for the prevention and treatment of prostate cancer in China (including Taiwan, Hong Kong and Macau).
License Property
Peptide name AE37 (li-Key/HER2/neu776-790)

AE37 is an immunotherapeutic vaccine for prostate cancer.  AE37, an Ii-Key-Hybrid molecule that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers, including breast, prostate, and bladder cancers.

Trade name AE37

Field of Use
AE37 peptide is to develop and sell products for the prevention and treatment of prostate cancer.

IPSCIO Record ID: 42526

License Grant
Under the Supplement Agreement, the company and Licensee each granted the other party, in the other party’s territory, exclusive, royalty-bearing licenses under certain patent rights and know-how to develop, manufacture and commercialize BOW070. Licensee’s territory consists of China, Hong Kong, Macau and Taiwan, and the Company’s territory consists of the rest of the world.
License Property
This Supplement adds the proprietary product, BOW070 (tocilizumab), a biosimilar version of ActemraTM, an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis (“BOW070”), as a New Collaboration Compound to the Collaboration Agreement. In the Collaboration agreement the parties have agreed to jointly develop and commercialize up to five (5) Collaboration Compounds, as determined by both parties.

ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

IPSCIO Record ID: 27631

License Grant
The Licensee has the exclusive right to develop, manufacture and commercialize Opdivo in all territories worldwide except Japan, South Korea and Taiwan (where the Licensor was responsible for all development and commercialization prior to the amendment). The alliance agreement was amended to provide for additional collaboration activities in Japan, South Korea and Taiwan pertaining to Opdivo and several other Licensee compounds including ipilimumab, lirilumab, urelumab and BMS-986016 (anti-LAG3). Both parties have the right and obligation to jointly develop and commercialize the compounds. The Licensee is responsible for supply of the product.
License Property
The agreement is to develop and commercialize Opdivo, an anti-PD-1 human monoclonal antibody being investigated as an anti-cancer treatment. Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) on T and NKT cells. It is being investigated as an anticancer treatment. It is in Phase III trials (which commenced in 2012) in non-small cell lung cancer, renal cell cancer and melanoma.
Field of Use
The parties jointly own a patent covering Opdivo as a composition of matter that expires in 2027 in the U.S. (excluding potential patent term extension). In December 2014, the FDA approved Opdivo for unresectable (inoperable) or metastatic melanoma, and disease progression following Yervoy and, if BRAF V600 mutation positive, a BRAF inhibitor. Opdivo was also approved in Japan in July 2014 for the same indication. The FDA has granted Fast Track designation for Opdivo in three tumor types non-small cell lung cancer, renal cell carcinoma and metastatic melanoma, and it is in the registrational process for melanoma and non-small cell lung cancer in the U.S. and Europe. The FDA granted Breakthrough Therapy designation for Hodgkin Lymphoma in 2014.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.